/Investor DB

Astellas Venture Management LLC — 2023 Investments

3 investments dated 2023 · listed companies and verified rows first · show all

Mogrify Limitedmogrify.co.ukin𝕏Series A · Oct 2023 · $17M

Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another.

BiotechDeep TechHealthtech

Julian Gough(Co-founder)inOwen Rackham(Co-founder)inJose Polo(Co-founder)inDarrin M. Disley(CEO)in

BoardJane Osbourn(Chair)

Co-investorsAhren Innovation CapitalParkwalk Advisors

Redonaredonatx.cominJul 2023

Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.

AI & Machine LearningBiotechBoston, US

George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKazumi Shiosaki(President & CEO)in

BoardMichal Silverberg(Director)

Co-investorsOUP (Osage University Partners)Sofinnova PartnersMPM BioImpact

Turn Biotechnologies, Inc.turn.bioAug 2023

mRNA/LNP based in vivo cell rejuvenation

Mountain View, US

Vittorio Sebastiano(Director)Marco Quarta(Director)Anja Krammer(Executive Officer, Director)Sergio Andres Ruiz-Chinchilla(Executive Officer)Ric Peterson(Executive Officer)

BoardDavid Gobel(Director)

Co-investorsFormic VenturesGaingelsMethuselah FundsKhosla VenturesShanda Group

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.